2026 Cell & Gene Therapy Symposium (CGTS)

Emerging Therapy Solutions’ CEO Ashley Hume joined a panel of industry leaders at the 2026 Cell & Gene Therapy Symposium (CGTS), hosted by the Association for Value-Based Cancer Care, to explore how evolving government policies are shaping the development, payment and delivery of cell and gene therapies.

Ashley brought the payer perspective and ETS experience to the session, “Government Innovation Agendas: Can Policy Keep Pace with CGT?” The discussion focused on what health plans need from manufacturers, providers and other stakeholders to support responsible CGT access.

It’s a conversation closely connected to the work ETS has led for 30 years: helping organizations anticipate emerging therapies, understand clinical and financial risk, and build strategies that make access to high-cost, complex care more sustainable.